Results 151 to 160 of about 181,344 (173)

Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer.

Journal of Clinical Oncology, 2021
e20593 Background: The receptor-ligand interaction between programmed cell death protein-1 (PD-1) and its ligands (PD-L1 and PD-L2) plays a critical role in tumor immune evasion and has become a therapeutic target in a number of cancer types, including extensive stage small cell lung cancer (ES-SCLC).
Ke (Kirsten) Zu, Jeanette Bæhr Georgsen, Peter Meldgaard, Anne Deitz, Mark Ayers, Maria Catherine Pietanza, Torben Steiniche   +6 more
openaire   +1 more source

Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

Lupus, 2020
Objective Programmed cell death protein 1 (PD-1) pathway plays important roles in systemic lupus erythematosus (SLE). We aimed to elucidate the association of serum soluble PD-1 (sPD-1) and related molecules with SLE and to explore their usefulness as biomarkers. Methods We retrospectively measured the serum levels of sPD-1, soluble PD-ligand 1 (sPD-L1)
Shinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi, Yashushi Kawaguchi, Masayoshi Harigai   +4 more
openaire   +2 more sources

LUP916517 Supplemental Material - Supplemental material for Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

2020
Supplemental material, LUP916517 Supplemental Material for Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity by Shinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi, Yashushi Kawaguchi and Masayoshi Harigai ...
Hirahara, Shinya, Katsumata, Yasuhiro, Hidenaga Kawasumi, Yashushi Kawaguchi, Harigai, Masayoshi   +4 more
openaire   +1 more source

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of Thoracic Oncology, 2021
Masayuki Shirasawa, Yuji Matsumoto, Hidehito Horinouchi   +2 more
exaly  

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis

Cancer Treatment Reviews, 2021
Keiichiro Mori, Benjamin Pradere, Fahad Quhal   +2 more
exaly  

Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis

Archives of Oral Biology, 2020
Hongzhi Quan, Liangjuan Fang
exaly  

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Cancer Control, 2022
Wenqi Qiu, Yunqing Qiu, Wei Yu
exaly  

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

Chest, 2017
Mónica Khunger, Adrian V Hernández, Peter J Mazzone   +2 more
exaly  

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

Histopathology, 2016
Dohee Kwon, Sehui Kim, Heounjeong Go
exaly  

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

European Journal of Cancer, 2014
Ching-Yao Yang, Mong-Wei Lin, Yih-Leong Chang   +2 more
exaly